机器人辅助根治性前列腺切除术后不同CAPRA风险组中阳性手术切缘与肿瘤学结局
该回顾性队列研究纳入1039例接受机器人辅助根治性前列腺切除术的前列腺癌患者,评估阳性手术切缘(PSM)在不同CAPRA风险组中对生化复发(BCR)和追加治疗的影响。结果显示,广泛PSM在所有风险组均与BCR和挽救放疗风险增加相关,而局灶PSM仅在高危组与追加治疗风险增加相关。
要点
- 广泛PSM在低、中、高危组均与BCR风险增加相关。
- 局灶PSM仅在高危组与BCR、挽救放疗和ADT风险增加相关。
- CAPRA风险组与PSM对BCR无显著交互作用(P=0.25)。
核心结论
- 广泛PSM在所有CAPRA风险组均与BCR风险增加相关。
- 局灶PSM仅在高危患者中与追加治疗风险增加相关。
研究设计与样本
- 回顾性队列研究,纳入1039例在欧洲单中心接受RARP的前列腺癌患者。
- PSM按范围分为局灶和广泛,采用CAPRA评分进行风险分层。
- BCR定义为前列腺特异性抗原>0.2 ng/mL,追加治疗包括挽救放疗和/或雄激素剥夺治疗。
主要发现
- 227例(21.8%)存在PSM。
- 广泛PSM vs 阴性切缘:低危组BCR HR 2.16(95%CI 2.09-8.29),中危组HR 3.76(95%CI 2.33-6.06),高危组HR 2.35(95%CI 1.03-5.38)。
- 广泛PSM vs 阴性切缘:低危组挽救放疗HR 3.75(95%CI 1.45-9.7),中危组HR 4.57(95%CI 2.47-8.43),高危组HR 9.32(95%CI 1.06-14.82)。
- 高危组局灶PSM vs 阴性切缘:BCR HR 5.79(95%CI 1.62-20.65),挽救放疗HR 9.32(95%CI 1.7-50.95),ADT HR 4.11(95%CI 1.08-15.57)。
- 低、中危组局灶PSM对BCR有 modest 影响,对挽救放疗或ADT无显著影响。
临床怎么用
- 术后应报告PSM范围(局灶或广泛)以辅助风险分层。
- 广泛PSM患者在各风险组均需加强BCR监测。
- 高危组局灶PSM患者也应警惕追加治疗风险。
局限性
- 回顾性单中心研究,可能存在选择偏倚。
- PSM范围评估可能受病理评估差异影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of a positive surgical margin (PSM) in relation to the risk of biochemical recurrence (BCR) and additional treatment in different preoperative Cancer of the Prostate Risk Assessment (CAPRA) risk groups after robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: Retrospective cohort study of 1039 patients subjected to RARP for prostate cancer at a single European institution. PSM was stratified by extent (focal extensive). The CAPRA score was used for risk group stratification. BCR was defined as a prostate-specific antigen level >0.2 ng/mL. Additional treatment was defined as salvage radiotherapy (sRT) and/or androgen-deprivation therapy (ADT). RESULTS: In total 227 patients had a PSM (21.8%). When compared to a negative surgical margin, an extensive PSM was associated with an increased risk of BCR (hazard ratio [HR] 2.16, 95% confidence interval [CI] 2.09-8.29; HR 3.76, 95% CI 2.33-6.06; HR 2.35, 95% CI 1.03-5.38) and sRT (HR 3.75, 95% CI 1.45-9.7; HR 4.57, 95% CI 2.47-8.43; HR 9.32, 95% CI 1.06-14.82) in the low-, intermediate- and high-risk groups, respectively. In high-risk patients a focal PSM was associated with an increased risk of BCR (HR 5.79, 95% CI 1.62-20.65), sRT (HR 9.32, 95% CI 1.7-50.95) and ADT (HR 4.11, 95% CI 1.08-15.57) whereas in low- and intermediate-risk patients a modest effect on BCR but no significant effect on sRT or ADT was found. We found no significant interaction between CAPRA risk group and PSM (P = 0.25). CONCLUSIONS: While an extensive PSM was associated with an increased risk of recurrence in all risk groups, a focal PSM was associated with additional treatment only among men with high-risk tumours.
引用
- Hagman A, Lantz A, Grannas D, et al. Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups. BJU Int. 2025. PMID: 40275471. doi:10.1111/bju.16732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。